Physical Disruption of Solid Tumors by Immunostimulatory Microrobots Enhances Antitumor Immunity
Source abstract
Abstract
Abstract The combination of immunotherapy with other forms of treatment is an emerging strategy for boosting antitumor responses. By combining multiple modes of action, these combinatorial therapies can improve clinical outcomes through unique synergisms. Here, a microrobot‐based strategy that integrates tumor tissue disruption with biological stimulation is shown for cancer immunotherapy. The microrobot is fabricated by loading bacterial outer membrane vesicles onto a self‐propelling micromotor, which can react with water to generate a propulsion force. When administered intratumorally to a solid tumor, the disruption of the local tumor tissue coupled with the delivery of an immunostimulatory payload leads to complete tumor regression. Additionally, treatment of the primary tumor results in the simultaneous education of the host immune system, enabling it to control the growth of distant tumors. Overall, this work introduces a distinct application of microrobots in cancer immunotherapy and offers an attractive strategy for amplifying cancer treatment efficacy when combined with conventional therapies.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Micro and Nano Robotics · Molecular Communication and Nanonetworks · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of NanoEngineering and Chemical Engineering Program University of California San Diego La Jolla CA 92093 USA
Moores Cancer Center University of California San Diego La Jolla CA 92093 USA
Funding
National Institutes of Health · Defense Threat Reduction Agency
References (57)
Show source-provided references
1. 10.1038/nature1067310.1038/nature10673 ↗
2. 10.1126/science.124948110.1126/science.1249481 ↗
3. 10.1038/s41571-019-0308-z10.1038/s41571-019-0308-z ↗
4. 10.1002/adma.20170396910.1002/adma.201703969 ↗
5. 10.1039/C8CS00896E10.1039/C8CS00896E ↗
6. 10.1002/adma.20200763010.1002/adma.202007630 ↗
7. 10.1038/nrclinonc.2016.2510.1038/nrclinonc.2016.25 ↗
8. 10.1126/scirobotics.aam643110.1126/scirobotics.aam6431 ↗
9. 10.4155/tde-2017-011310.4155/tde-2017-0113 ↗
10. 10.1016/j.apmt.2020.10069410.1016/j.apmt.2020.100694 ↗
11. 10.1021/acsnano.8b0661010.1021/acsnano.8b06610 ↗
12. 10.1021/acs.nanolett.9b0283210.1021/acs.nanolett.9b02832 ↗
13. 10.1002/anie.20201368910.1002/anie.202013689 ↗
14. 10.1002/smll.20190618410.1002/smll.201906184 ↗
15. 10.1038/s41467-017-00309-w10.1038/s41467-017-00309-w ↗
16. 10.1002/smll.20190715010.1002/smll.201907150 ↗
17. 10.1038/s41467-020-19322-710.1038/s41467-020-19322-7 ↗
18. 10.1002/adhm.20200090010.1002/adhm.202000900 ↗
19. 10.1021/acs.nanolett.0c0443810.1021/acs.nanolett.0c04438 ↗
20. 10.1007/s42242-020-00072-w10.1007/s42242-020-00072-w ↗
21. 10.1002/adma.20170675910.1002/adma.201706759 ↗
22. 10.1002/adtp.20190009610.1002/adtp.201900096 ↗
23. 10.1002/adtp.20180005610.1002/adtp.201800056 ↗
24. 10.1038/nature1537310.1038/nature15373 ↗
25. 10.1038/nmat244210.1038/nmat2442 ↗
26. 10.1002/adhm.20200123610.1002/adhm.202001236 ↗
27. 10.3389/fbioe.2018.0017010.3389/fbioe.2018.00170 ↗
28. 10.1038/nnano.2017.11310.1038/nnano.2017.113 ↗
29. 10.1038/nnano.2015.29210.1038/nnano.2015.292 ↗
30. 10.1073/pnas.190402211610.1073/pnas.1904022116 ↗
31. 10.1038/nri383710.1038/nri3837 ↗
32. 10.1021/acsabm.0c0107210.1021/acsabm.0c01072 ↗
33. 10.1038/s41467-017-00729-810.1038/s41467-017-00729-8 ↗
34. 10.1002/adma.20200208510.1002/adma.202002085 ↗
35. 10.1039/c3nr01458d10.1039/c3nr01458d ↗
36. 10.1016/j.bbamem.2007.07.02010.1016/j.bbamem.2007.07.020 ↗
37. 10.1016/j.gca.2012.10.03110.1016/j.gca.2012.10.031 ↗
38. 10.1179/imr.1993.38.3.13810.1179/imr.1993.38.3.138 ↗
39. 10.1038/s41418-018-0214-410.1038/s41418-018-0214-4 ↗
40. 10.3389/fimmu.2017.0032710.3389/fimmu.2017.00327 ↗
41. 10.1128/MMBR.00031-0910.1128/MMBR.00031-09 ↗
42. 10.1038/nature1400110.1038/nature14001 ↗
43. 10.1158/0008-5472.CAN-13-335610.1158/0008-5472.CAN-13-3356 ↗
44. 10.1016/j.cell.2010.01.02510.1016/j.cell.2010.01.025 ↗
45. 10.1016/j.jaci.2005.05.03610.1016/j.jaci.2005.05.036 ↗
46. 10.1016/j.immuni.2009.09.01410.1016/j.immuni.2009.09.014 ↗
47. 10.1111/j.1600-065X.2008.00616.x10.1111/j.1600-065X.2008.00616.x ↗
48. 10.1038/nrc.2018.610.1038/nrc.2018.6 ↗
49. 10.1007/s10585-018-9896-810.1007/s10585-018-9896-8 ↗
50. 10.1158/0008-5472.CAN-16-153610.1158/0008-5472.CAN-16-1536 ↗
51. 10.1038/nrclinonc.2013.20810.1038/nrclinonc.2013.208 ↗
52. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
53. 10.1002/adma.20170400710.1002/adma.201704007 ↗
54. 10.1002/adma.20190125510.1002/adma.201901255 ↗
55. 10.1002/adma.20200180810.1002/adma.202001808 ↗
56. 10.1021/nl504798g10.1021/nl504798g ↗
57. 10.1002/anie.20190628010.1002/anie.201906280 ↗